Bridging the Diversity Gap in Rare Disease Clinical Trials with Dr. Harsha Rajasimha, Ph.D.
November 8, 2023
As the clinical trials industry is still scrambling with diversity concerns, FDA
's Racial and Ethnic Diversity Plan is now emphasizing biopharmaceutical sponsors to embrace and accelerate the clinical trials equitably.
Propelling his voice towards removing disparities in diversity and ethnicity, our Founder and CEO, Dr. Harsha K Rajasimha
, Ph.D., calls to foster the gaps arising in clinical research. While discussing the topic, “Bridging the Diversity Gap in Rare Disease Clinical Trials”, he emphasized the importance of closing the gaps in these trials, as it can benefit all patients and clinical stakeholders.
He also believes that early detection and diagnosis of rare diseases like ALS, Cystic Fibrosis, Thalassemia, Hemophilia, and others can significantly improve patient outcomes and prognosis.
For more, listen to this podcast from Managed Healthcare Executive
: Visit Here